Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM
Joint Authors
Sarandöl, Emre
Guclu, Metin
Oz Gul, Ozen
Cander, Soner
Unal, Oguzkaan
Ozkaya, Guven
Ersoy, Canan
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-07-27
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Aim.
To investigate the efficacy of combined therapy of insulin and rosiglitazone on metabolic and inflammatory parameters, insulin sensitivity, and adipocytokine levels in patients with type 1 diabetes mellitus (type 1 DM).
Material and Methods.
A total of 61 adults with type 1 DM were randomly and prospectively assigned in open-label fashion to take insulin and rosiglitazone 4 mg/day (n=30) or insulin alone (n=31) for a period of 18 weeks while undergoing insulin therapy without acute metabolic complications.
Results.
Combination therapy did not significantly improve metabolic and inflammatory parameters, insulin sensitivity, and adiponectin levels.
While leptin and resistin levels decreased in both groups (group 1: resistin 6.96 ± 3.06 to 4.99 ± 2.64, P=0.006; leptin 25.8 ± 17.6 to 20.1 ± 12.55, P=0.006; group 2: resistin 7.16 ± 2.30 to 5.57±2.48, P=0.031; leptin 16.72 ± 16.1 to 14.0 ± 13.4, P=0.007) Hgb and fibrinogen levels decreased only in group 1 (Hgb 13.72 ± 1.98 to 13.16 ± 1.98, P=0.015, and fibrinogen 4.00 ± 1.08 to 3.46 ± 0.90, P=0.002).
Patients in both groups showed weight gain and the incidence of hypoglycemia was not lower.
Discussion.
The diverse favorable effects of TZDs were not fully experienced in patients with type 1 DM.
These results are suggesting that insulin sensitizing and anti-inflammatory characteristics of TZDs were likely to be more pronounced in patients who were not totally devoid of endogenous insulin secretion.
American Psychological Association (APA)
Guclu, Metin& Oz Gul, Ozen& Cander, Soner& Unal, Oguzkaan& Ozkaya, Guven& Sarandöl, Emre…[et al.]. 2015. Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM. Journal of Diabetes Research،Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1068008
Modern Language Association (MLA)
Guclu, Metin…[et al.]. Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM. Journal of Diabetes Research No. 2015 (2015), pp.1-9.
https://search.emarefa.net/detail/BIM-1068008
American Medical Association (AMA)
Guclu, Metin& Oz Gul, Ozen& Cander, Soner& Unal, Oguzkaan& Ozkaya, Guven& Sarandöl, Emre…[et al.]. Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM. Journal of Diabetes Research. 2015. Vol. 2015, no. 2015, pp.1-9.
https://search.emarefa.net/detail/BIM-1068008
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1068008